文献速递皮肤肿瘤

靶向抗癌小分子药物皮肤毒性第一部分:毒性机制

Cutaneous Toxicities of Small Molecules in Targeted Cancer Therapy Part I - Mechanisms of Toxicity.
PubMed 文献 · J Am Acad Dermatol · 2026-01-30

本文为继续医学教育文章第一部分,聚焦小分子抑制剂(SMI)在靶向抗癌治疗中皮肤不良事件的毒性机制。文章指出SMI因广谱适用性和独特副作用谱而成为综述重点,系统回顾了相关皮肤毒性的发生机制。

要点

  • 小分子抑制剂是靶向抗癌治疗两大支柱之一,皮肤毒性机制独特。
  • 本文为继续医学教育文章第一部分,聚焦SMI皮肤毒性机制。
  • 传统化疗为非特异性细胞毒,靶向治疗旨在抑制致癌和肿瘤生长通路。

核心结论

  • 本综述聚焦小分子抑制剂(SMI)的皮肤毒性机制,作为继续医学教育文章第一部分。

研究设计与样本

  • 综述文章,聚焦SMI因广谱适用性、药物数量快速增长及独特副作用谱。

主要发现

  • 传统化疗作为细胞内毒物干扰细胞分裂或诱导DNA损伤,产生显著脱靶细胞毒性。
  • 靶向治疗旨在更特异性地抑制致癌和肿瘤生长相关通路。
  • SMI与抗体类药物是靶向治疗的两大支柱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in the understanding of cancer biology have led to a shift toward more precise, targeted anticancer therapies. Traditional chemotherapy acts as an intracellular poison to disrupt cell division or induce DNA damage resulting in cytotoxicity1. However, the effects of traditional chemotherapy are not relegated to neoplastic tissue, resulting in significant off-target cytotoxicity2. Targeted therapies were developed to provide a more specific approach to cancer treatment, focused on inhibiting the pathways involved in carcinogenesis and tumor growth. Small molecule inhibitors (SMIs) and antibody-based therapies are the two main pillars of this approach3. This review focuses on SMIs given their broad applicability across tumor types, rapidly expanding number of agents, and unique side effect profiles4,5. Part I of this continuing medical education article reviews mechanisms of toxicity of dermatologic adverse events associated with SMIs.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Nykaza I, Kwong B, Gordon A, et al. Cutaneous Toxicities of Small Molecules in Targeted Cancer Therapy Part I - Mechanisms of Toxicity. J Am Acad Dermatol. 2026. PMID: 41621676. doi:10.1016/j.jaad.2026.01.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。